BioAtla Announces 1-for-50 Reverse Stock Split Merger

The latest update is out from BioAtla ( (BCAB) ).

On April 2, 2026, BioAtla filed a certificate of merger in Delaware to implement a previously approved Agreement and Plan of Merger between the company and its wholly owned subsidiary, BA Merger Sub, Inc., which had been adopted by the board and executed on January 30, 2026. The merger will become effective at 12:01 a.m. Eastern Time on April 6, 2026, with BA Merger Sub merging into BioAtla, BioAtla continuing as the surviving corporation, and every 50 outstanding or treasury shares of BioAtla common stock automatically converting into one share, effectively executing a 1-for-50 reverse stock split that consolidates the share base and may impact trading dynamics and existing shareholders’ proportional holdings.

The transaction preserves BioAtla’s existing amended and restated certificate of incorporation for the surviving entity, signaling a structural share consolidation rather than a change in the company’s corporate identity or foundational governance documents. The executed merger agreement is maintained at the company’s San Diego office and is available to stockholders upon request, underscoring a formal, internal reorganization aimed at tightening the capital structure while keeping the operating company and its legal framework intact.

The most recent analyst rating on (BCAB) stock is a Sell with a $0.14 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.

Spark’s Take on BCAB Stock

According to Spark, TipRanks’ AI Analyst, BCAB is a Neutral.

Overall score is held down primarily by weak financial performance (persistent losses, ongoing cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Corporate events add significant uncertainty (restructuring and Nasdaq listing risk). These are only partially offset by more constructive earnings-call updates around trial/FDA alignment and partnering efforts.

To see Spark’s full report on BCAB stock, click here.

More about BioAtla

BioAtla, Inc. is a Delaware‑incorporated biotechnology company whose business centers on developing therapeutic products, typically in the biopharmaceutical space, with operations headquartered in San Diego, California. Its corporate structure and governance follow the Delaware General Corporation Law, reflecting a focus on capital markets access and scalable growth in the life sciences sector.

Average Trading Volume: 2,300,856

Technical Sentiment Signal: Sell

Current Market Cap: $11.15M

See more data about BCAB stock on TipRanks’ Stock Analysis page.